SCHEMBL2648409

SCHEMBL2648409

CCOC(=O)CNS(=O)(=O)c1nnc(N)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.48
CA2 P00918 3/20 0.44
CA9 Q16790 3/20 0.44
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA4 P22748 2/20 0.44
CA6 P23280 2/20 0.44
CA5A P35218 2/20 0.44
CA7 P43166 2/20 0.44
CA13 Q8N1Q1 2/20 0.44
CA14 Q9ULX7 2/20 0.44
CA5B Q9Y2D0 2/20 0.44
CA3 P07451 1/20 0.44
POLB P06746 2/20 0.41
HPGD P15428 4/20 0.40
HTT P42858 2/20 0.40
HSD17B10 Q99714 2/20 0.40
GAA P10253 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
PKM P14618 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2647777 0.81 ALDH1A1 (0.46) ALDH1A1CA2CA9CA12CA1
SCHEMBL3902867 0.77 CA2 (0.53) ALDH1A1CA2CA9CA12CA1
SCHEMBL2648696 0.77 ALDH1A1 (0.41) ALDH1A1CA2CA9CA12CA1
SCHEMBL1240657 0.76 SMN1; SMN2 (0.53) ALDH1A1HPGDHSD17B10GAASMN1; SMN2
SCHEMBL973139 0.75 ALDH1A1 (0.41) ALDH1A1CA2CA9CA12CA1
SCHEMBL4417022 0.75 CA1 (0.39) ALDH1A1CA2CA9CA12CA1
SCHEMBL2647697 0.74 CA2 (0.54) ALDH1A1CA2CA9CA12CA1
SCHEMBL2647780 0.74 ALDH1A1 (0.50) ALDH1A1CA2CA9CA12CA1
SCHEMBL2012444 0.69 GAA (0.52) ALDH1A1HPGDHSD17B10GAASMN1; SMN2
SCHEMBL12643844 0.69 PPID (0.56) ALDH1A1POLBHPGDHTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 US disclosed
EP-1904466-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
WO-2007006760-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators GCK, GCKR, UCK2 ALDH1A1 3782/4885CA2 1243/4885CA9 1314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.